Department of Herbology, College of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea.
College of Pharmacy & Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, 03760, Korea.
Chin J Integr Med. 2024 Feb;30(2):125-134. doi: 10.1007/s11655-023-3548-9. Epub 2023 Apr 29.
To investigate the effects of Clean-DM1 (C-DM1), a polyherbal formulation of Radix Scrophulariae, Radix Astragali, Rhizoma Atractylodis, and Radix Salviae Miltiorrhizae, on high-fat diet (HFD)-induced diabetes mice.
The information about active components of C-DM1 extract and molecular mechanism was obtained from network pharmacology analysis. Main compounds of C-DM1 extract by high performance liquid chromatography-mass spectrometry (HPLC-MS) analysis were conducted for quality control. For in vivo study, mice were induced diabetes by HFD for 12 weeks. The mice in the normal group (Nor) were maintained with a regular diet and treated with saline by gavage. The HFD model mice were randomly divided into 3 groups, including a HFD diabetic model group, a C-DM1 extract-administered group (C-DM1, 500 mg/kg), and metformin-administered groups (Met, 500 mg/kg), 8 mice in each group. Food intake, body weight (BW), and fasting blood glucose (FBG) levels were recorded weekly for 4 weeks. After 4 weeks of treatment, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood glucose, low-density lipoprotein cholesterol (LDL-C) were determined using an automated clinical chemistry analyzer, and homeostatic model for assessing insulin resistance (HOMA-IR) levels and oral glucose tolerance test (OGTT) were detected. The histopathological changes of liver and pancreatic tissues were observed by hematoxylin-eosin staining. Insulin receptor substrate (IRS)/phosphatidylinositol 3 kinase (PI3K)/ protein kinase B (AKT) and adenosine 5'-monophosphate-activated protein kinase (AMPK) expressions in liver and pancreas tissues were detected by Western blot analysis.
HPLC-MS identified dihydroisotanshinone, dihydroisotanshinone I, cryptotanshinone, harpagoside, and atractyloside A in C-DM1 extract. The administration of C-DM1 extract significantly decreased body weight, calorie intake, and the levels of blood glucose and insulin in the diabetic mice (P<0.05 or P<0.01). The C-DM1 extract administration improved the impaired glucose tolerance and insulin resistance in the diabetic mice and significantly decreased the levels of LDL-C, ALT and AST (P<0.01). The C-DM1 extract inhibited the histopathological changes of fatty liver and hyperplasia of pancreatic islets in the diabetic mice. The C-DM1 extract significantly increased the phosphorylation of IRS, AKT, and AMPK and the expression of PI3K in pancreas and liver tissues (P<0.05 or P<0.01), which was consistent with the analysis results of network pharmacology.
C-DM1 extract improved diabetes symptoms in long-term HFD-induced mice by regulation of IRS/PI3K/AKT and AMPK expressions in pancreas and liver tissues, suggesting that C-DM1 formulation may help prevent the progression of T2DM.
研究复方地黄(C-DM1)对高脂肪饮食(HFD)诱导的糖尿病小鼠的作用。
采用网络药理学分析获得 C-DM1 提取物的活性成分信息和分子机制。采用高效液相色谱-质谱(HPLC-MS)分析 C-DM1 提取物的主要化合物,进行质量控制。在体内研究中,小鼠用 HFD 诱导 12 周糖尿病。正常组(Nor)的小鼠维持正常饮食,并通过灌胃给予生理盐水。将 HFD 模型小鼠随机分为 3 组,包括 HFD 糖尿病模型组、C-DM1 提取物给药组(C-DM1,500mg/kg)和二甲双胍给药组(Met,500mg/kg),每组 8 只。每周记录 4 周的饮食摄入量、体重(BW)和空腹血糖(FBG)水平。治疗 4 周后,采用自动临床化学分析仪测定丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、血糖、低密度脂蛋白胆固醇(LDL-C),检测稳态模型评估胰岛素抵抗(HOMA-IR)水平和口服葡萄糖耐量试验(OGTT)。用苏木精-伊红染色观察肝和胰腺组织的组织病理学变化。采用 Western blot 分析检测肝和胰腺组织中胰岛素受体底物(IRS)/磷酸肌醇 3 激酶(PI3K)/蛋白激酶 B(AKT)和腺苷 5'-单磷酸激活的蛋白激酶(AMPK)的表达。
HPLC-MS 鉴定出 C-DM1 提取物中的二氢异丹参酮、二氢异丹参酮 I、隐丹参酮、哈巴苷和苍术苷 A。C-DM1 提取物给药显著降低了糖尿病小鼠的体重、热量摄入以及血糖和胰岛素水平(P<0.05 或 P<0.01)。C-DM1 提取物给药改善了糖尿病小鼠的葡萄糖耐量受损和胰岛素抵抗,并显著降低了 LDL-C、ALT 和 AST 水平(P<0.01)。C-DM1 提取物抑制了糖尿病小鼠的脂肪肝和胰岛增生的组织病理学变化。C-DM1 提取物显著增加了胰腺和肝脏组织中 IRS、AKT 和 AMPK 的磷酸化以及 PI3K 的表达(P<0.05 或 P<0.01),与网络药理学分析结果一致。
C-DM1 提取物通过调节胰腺和肝脏组织中 IRS/PI3K/AKT 和 AMPK 的表达,改善了长期 HFD 诱导的糖尿病小鼠的糖尿病症状,提示 C-DM1 配方可能有助于预防 T2DM 的进展。